Ainnocence Company Profile

Background

Overview

Ainnocence is a biotechnology company founded in 2021, specializing in AI-driven drug discovery and development. The company leverages advanced computational techniques to accelerate the design and optimization of therapeutic agents, including small molecules, antibodies, and gene therapies. By integrating artificial intelligence with biological data, Ainnocence aims to revolutionize the drug discovery process, making it more efficient and cost-effective.

Mission and Vision

Ainnocence's mission is to harness the power of artificial intelligence to expedite the development of life-saving therapies. The company's vision is to transform the pharmaceutical industry by providing innovative solutions that address complex biological challenges, thereby improving patient outcomes and advancing global health.

Primary Area of Focus

The company's primary focus is on utilizing AI to enhance various stages of drug discovery, including target identification, lead optimization, and preclinical development. Ainnocence's platforms are designed to streamline these processes, reducing the time and resources traditionally required to bring new therapies to market.

Industry Significance

In the rapidly evolving biotechnology sector, Ainnocence stands out for its commitment to integrating AI with drug discovery. The company's innovative approach addresses longstanding challenges in the industry, such as high costs and lengthy development timelines, positioning it as a significant player in the future of pharmaceutical research and development.

Key Strategic Focus

Core Objectives

Accelerate Drug Discovery: Utilize AI to expedite the identification and optimization of therapeutic agents.

Enhance Efficiency: Streamline the drug development process to reduce time and costs.

Expand Therapeutic Reach: Develop treatments for a broad range of diseases, including those with unmet medical needs.

Specific Areas of Specialization

Protein Design: Develop and optimize proteins for therapeutic applications.

Antibody Engineering: Create and refine antibodies for targeted therapies.

Gene Therapy: Design gene vectors and optimize gene delivery systems.

Key Technologies Utilized

SentinusAI®: A proprietary AI platform for protein design and optimization.

CarbonAI®: An AI engine focused on small-molecule and PROTAC design.

BioSynthAI™: An AI-driven platform for synthetic biology product discovery.

Primary Markets Targeted

Ainnocence primarily targets the biotechnology and pharmaceutical industries, collaborating with companies and research institutions to develop novel therapies across various therapeutic areas.

Financials and Funding

Funding History

Ainnocence has completed two funding rounds, raising a total of $4.6 million. The most recent round was a seed funding round, closed in April 2025, with a valuation of $30 million.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The funds raised are intended to support the expansion of Ainnocence's AI platforms, enhance research and development capabilities, and facilitate strategic partnerships to advance the company's mission.

Pipeline Development

Key Pipeline Candidates

SentinusAI®: A platform for de novo antibody discovery and affinity maturation, targeting G Protein-Coupled Receptors (GPCRs) and other therapeutic targets.

CarbonAI®: An engine for small-molecule and PROTAC design, focusing on multi-objective pharmacological profile optimization.

BioSynthAI™: A platform for synthetic biology product discovery, including gene design and strain optimization.

Stages of Development

These platforms are in various stages of development, with ongoing enhancements to improve their capabilities and applications in drug discovery.

Target Conditions

The platforms aim to address a wide range of conditions, including cancers, autoimmune diseases, and genetic disorders.

Anticipated Milestones

Ainnocence anticipates achieving significant milestones in the near future, including the successful application of its platforms in clinical settings and the development of novel therapies for previously untreatable conditions.

Technological Platform and Innovation

Proprietary Technologies

SentinusAI®: A sequence-based AI platform for protein design, achieving a 50% success rate in de novo design and an 85.7% success rate in affinity maturation.

CarbonAI®: An AI engine for small-molecule and PROTAC design, capable of compressing discovery timelines from years to weeks.

BioSynthAI™: An AI-driven platform for synthetic biology product discovery, optimizing protein and enzyme activity through in-silico design.

Significant Scientific Methods

Sequence-Based Modeling: Utilizing protein sequence data to predict functions and optimize designs without relying on 3D structural information.

Multi-Objective Optimization: Balancing multiple therapeutic properties to identify optimal candidates.

Generative AI Models: Employing advanced AI algorithms to generate novel molecular structures with desired properties.

Leadership Team

Key Executives

Dr. Lurong Pan: Founder and CEO. Dr. Pan has a background in biomedical sciences and computer science, with experience in AI applications in biotechnology.

Junfeng Wu: Director of Artificial Intelligence. Wu specializes in AI and machine learning, focusing on their applications in drug discovery.

Kyle Brewer: Drug Development Advisor. Brewer brings expertise in pharmaceutical development and regulatory affairs.

Amalie Moyna Lobel: Research Engineer/Business Development. Lobel combines research engineering skills with business development experience.

Kevin Jin: Senior AI Scientist. Jin focuses on the development and application of AI models in therapeutic design.

Youtso: Marketing and Communications Associate. Youtso manages marketing strategies and communications.

Angielyn Brioso: Client Success Manager. Brioso ensures client satisfaction and manages client relationships.

Cheng: Communications Manager. Cheng oversees internal and external communications.

Competitor Profile

Market Insights and Dynamics

The biotechnology industry is experiencing rapid growth, with increasing investments in AI-driven drug discovery platforms. Companies are focusing on reducing development timelines and costs while improving the success rates of new therapies.

Competitor Analysis

Generate Biomedicines: Utilizes machine learning and biological data to design novel proteins for therapeutic applications.

Insitro: Combines machine learning with high-throughput biology to model disease states and design therapeutic interventions.

Galactica Biotech: Applies analytical methods, including machine learning, to identify new uses for molecules within the pharmaceutical industry.

Strategic Collaborations and Partnerships

Ainnocence has engaged in strategic collaborations to enhance its platform capabilities and expand its market reach. Notably, in January 2026, Ainnocence partnered with Phase Advance to integrate AI-driven drug design with predictive modeling of clinical outcomes, aiming to reduce drug development timelines and clinical trial risks.

Operational Insights

Ainnocence differentiates itself through its sequence-based AI platforms, which eliminate the need for 3D structural data, reducing computational costs and time. This approach allows for rapid virtual screening and optimization of therapeutic candidates, providing a competitive edge in the biotechnology sector.

Strategic Opportunities and Future Directions

Ainnocence is well-positioned to capitalize on the growing demand for AI-driven solutions in drug discovery. Future opportunities include expanding its platform applications to new therapeutic areas, enhancing collaboration with pharmaceutical companies, and advancing the development of novel therapies for complex diseases.